Eli Lilly & Co. (LLY)

109.70
1.80 1.67
NYSE : Health Technology
Prev Close 107.90
Open 108.35
Day Low/High 108.22 / 110.10
52 Wk Low/High 104.17 / 132.13
Volume 1.76M
Avg Volume 3.54M
Exchange NYSE
Shares Outstanding 965.43M
Market Cap 104.61B
EPS 3.10
P/E Ratio 25.74
Div & Yield 2.58 (2.34%)

Radius Gives up Gains From Drug Approval

Been two fairly uneventful days of trading, as far as the market indexes go, sitting in for Doug Kass here on the Daily Diary. Major indices are slightly down as we head into the last two hours of the trading week. Getting a few questions on Radius ...

The Good, the Bad and the Ugly (Mid-Afternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...

Today's Takeaways and Observations (3PM Edition)

I spent a lot of time on the (respectful) Rosenberg/Kass debate on economic growth and interest rates today:   * And Now A Word From Dennis Rosenberg  * And Now A Word From Dennis Rosenberg (Part Deux)  * And the Rosenberg Empire Strikes Again  * Ju...

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.

Takeaways and Observations (3PM Edition)

I started the day with an important piece on bonds - at least I hope so. Sell 'em, short 'em!    Trade of the Week - long TBT (consistent with above).  Well off the opening, at $37.60 now - and that's a good thing.   So far, so good.  At 230PM yield...

Stocks That Are Changing Direction

Stocks That Are Changing Direction

These charts are showing bullish or bearish reversals.

Cramer: Have Faith in International Strength

Cramer: Have Faith in International Strength

Because there are other things that will take the wind out of your sails.

Wake Up Wall Street

Wake Up Wall Street

UAL's earnings are expected today.

Jim Cramer: If There Is a Giant Selloff, I Like Eli Lilly

Jim Cramer: If There Is a Giant Selloff, I Like Eli Lilly

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said that if there is a giant selloff in the broader markets, he likes shares of Eli Lilly LLY.

Takeaways and Observations (Early Edition)

"Doug Kass wrote an article today about how he fears the lack of fear in this market. I agree with Doug that lack of fear is an issue, but it goes further than that. What this market has missed for quite some time is strong emotion. There may not be...

Cramer: We Have Nothing to Distinguish the Stocks Right Now

Cramer: We Have Nothing to Distinguish the Stocks Right Now

We know that we are in the era when index managers are ascendant.

Takeaways and Observations

Let me teach you how to Dougie. Consumer confidence is a coincident/lagging indicator. And excitement over the print, is (quite frankly) "first level thinking." As support, check out these two charts of the day -- it's "second level thinking." Snap ...

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Get your plan in place, but understand that the Republic is not in jeopardy.

Takeaways & Observations

"I had nothing to offer anybody except my own confusion." -- Jack Kerouac  So, color me confused. But I will persevere and write "Takeaways!"  While a lot didn't make sense, I suspect many traders/investors were caught "offsides."  Peter Boockvar do...

Takeaways and Observations

  "Wishin' and hopin' And thinkin' and prayin'..."  -- Dusty Springfield, Wishin' and Hopin'  The gap from last week's presidential speech was filled this afternoon.  I am more negative than most and more negative than I have been in a while.  Liter...

Eli Lilly: Here's One Drug Company Ready to Rally

Eli Lilly: Here's One Drug Company Ready to Rally

Traders should look to go long on a close above $84.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Cowen Health Care Conf.

Cramer: Top 10 Bull Markets Right Now

Cramer: Top 10 Bull Markets Right Now

Bull market number one, perhaps of all time: the financials.

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Snapchat's Parent Prices IPO at Low End of Expectations

Snapchat's Parent Prices IPO at Low End of Expectations

Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.

Takeaways and Observations

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters.  I covered last evening's Procter & Gamble short for a profit.  "For Traders Only."...

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Two industries should largely be avoided under this administration: pharma and retail.

Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump

Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump

Eli Lilly reaffirms its 2017 guidance after reporting higher sales and earnings in its latest quarter.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.